DB:5MC1

Stock Analysis Report

Executive Summary

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer.


Snowflake Analysis

Worrying balance sheet with weak fundamentals.

Share Price & News

How has Leap Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 5MC1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

19.6%

5MC1

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-24.3%

5MC1

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: 5MC1 underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 5MC1 matched the German Market which returned -17.5% over the past year.


Shareholder returns

5MC1IndustryMarket
7 Day19.6%11.2%7.3%
30 Day-41.7%-5.3%-17.9%
90 Day27.6%-21.9%-25.8%
1 Year-24.3%-24.3%-4.9%-5.1%-15.1%-17.7%
3 Year-82.8%-82.8%17.7%16.5%-18.7%-25.6%
5 Yearn/a-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is Leap Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Leap Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Leap Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Leap Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Leap Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-9.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 5MC1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 5MC1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 5MC1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 5MC1's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 5MC1's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 5MC1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Leap Therapeutics performed over the past 5 years?

-13.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 5MC1 is currently unprofitable.

Growing Profit Margin: 5MC1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 5MC1 is unprofitable, and losses have increased over the past 5 years at a rate of -13.5% per year.

Accelerating Growth: Unable to compare 5MC1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 5MC1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 5MC1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Leap Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 5MC1 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 5MC1 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 5MC1 is debt free.

Reducing Debt: 5MC1's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 5MC1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 5MC1's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 5MC1 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 5MC1 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -17.9% each year


Next Steps

Dividend

What is Leap Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 5MC1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 5MC1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 5MC1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 5MC1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 5MC1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

9.2yrs

Average management tenure


CEO

Chris Mirabelli (65yo)

9.17s

Tenure

US$678,607

Compensation

Dr. Christopher K. Mirabelli, also known as Chris, Ph.D., serves as the President of DecImmune Therapeutics, Inc. Dr. Mirabelli serves as the Managing Director at HealthCare Ventures LLC since 2000. He se ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD678.61K) is above average for companies of similar size in the German market ($USD432.27K).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Christopher Mirabelli
Chairman9.17yrsUS$678.61kno data
Douglas Onsi
CFO, General Counselno dataUS$682.09k0.96% $499.3k
Augustine Lawlor
Chief Operating Officer4.17yrsUS$680.20kno data
Walter Newman
Senior Research Fellowno datano datano data

9.2yrs

Average Tenure

65yo

Average Age

Experienced Management: 5MC1's management team is seasoned and experienced (9.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Christopher Mirabelli
Chairman9.17yrsUS$678.61kno data
Douglas Onsi
CFO, General Counselno dataUS$682.09k0.96% $499.3k
James Cavanaugh
Non-Employee Director4.17yrsUS$108.27kno data
Thomas Dietz
Lead Independent Directorno dataUS$122.70kno data
Nissim Mashiach
Non-Employee Director3.17yrsUS$108.26kno data
Joseph Loscalzo
Non-Employee Director4.17yrsUS$101.88kno data
William Li
Non-Employee Director3.17yrsUS$101.88kno data
Carl Nathan
Member of Scientific Advisory Boardno datano datano data
Eric Winer
Member of Scientific Advisory Boardno datano datano data
David Tuveson
Member of Scientific Advisory Boardno datano datano data

4.2yrs

Average Tenure

58yo

Average Age

Experienced Board: 5MC1's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 59.7%.


Top Shareholders

Company Information

Leap Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Leap Therapeutics, Inc.
  • Ticker: 5MC1
  • Exchange: DB
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$57.637m
  • Listing Market Cap: US$51.983m
  • Shares outstanding: 35.80m
  • Website: https://www.leaptx.com

Number of Employees


Location

  • Leap Therapeutics, Inc.
  • 47 Thorndike Street
  • Suite B1-1
  • Cambridge
  • Massachusetts
  • 2141
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LPTXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJan 2017
5MC1DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2017

Biography

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company’s clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 00:15
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.